NEO — NEOGENOMICS INC
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 1077183 ·
Last close
$14.11
Market Cap
$1.84B
52W High
$15.57
52W Low
$7.62
ADV30
3,118,673
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 186,672,000 | 80,864,000 | -18,241,000 | -17,106,000 | 1,346,531,000 | 146,143,000 | 517,771,000 |
| Dec 2025 | 190,170,000 | 83,343,000 | -12,788,000 | -9,881,000 | 1,359,830,000 | 159,618,000 | 523,268,000 |
| Sep 2025 | 187,797,000 | 80,446,000 | -19,928,000 | -27,129,000 | 1,374,780,000 | 164,117,000 | 536,490,000 |
| Jun 2025 | 181,330,000 | 77,258,000 | -27,587,000 | -45,092,000 | 1,393,950,000 | 154,723,000 | 539,910,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$22,420,000
Investing CF
$-20,896,000
Financing CF
$-201,575,000
CapEx
$-27,508,000
Dividends Paid
—
Buybacks
$-338,000
EPS Diluted TTM
$-0.77
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-450,912,000
Inventory
$29,837,000
Receivables
$167,424,000
ST Investments
$0
EBIT TTM
$-99,456,000
Pretax Income TTM
$-102,189,000
Interest Exp TTM
$2,733,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$745,969,024
EBITDA
$4,267,000
Free Cash Flow
$33,170,624
Enterprise Value
$2,180,405,504
Total Cash
$146,143,008
Total Debt
$408,528,992
Shares Out
130,211,780
Trailing EPS
$-0.77
Book Value
$6.39
ROE
-11.6%
ROA
-2.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 727,332,000 | -88,128,000 | -108,025,000 | 1,359,830,000 | 523,268,000 | — | 5,230,000 |
| Dec 2024 | 660,566,000 | -85,448,000 | -78,726,000 | 1,638,038,000 | 735,699,000 | — | 7,023,000 |
| Dec 2023 | 591,643,000 | -96,648,000 | -87,968,000 | 1,681,229,000 | 739,692,000 | — | -1,953,000 |
| Dec 2022 | 509,728,000 | -153,107,000 | -144,250,000 | 1,740,034,000 | 742,011,000 | — | -65,993,000 |
TTM Snapshot
Revenues TTM
$569,900,000
NetIncome TTM
$-102,777,000
OpCashFlow TTM
$0
Assets (Latest)
$1,638,038,000
Forward EPS
$0.36
Max Pain — expiry 2026-12-18
max pain strike: $10.00 · spot: $14.11 · call oi: 6,521 · put oi: 77Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| USA | LIBERTY ALL STAR EQUITY FUND | $1.83B | $5.94 | — |
| MH | McGraw Hill, Inc. | $1.88B | $9.82 | — |
| PAEXY | Parex Resources Inc./ADR | $1.79B | $18.63 | — |
| TY | TRI-CONTINENTAL Corp | $1.89B | $35.50 | — |
| NAC | Nuveen California Quality Municipal Income Fund | $1.89B | $12.10 | — |
News headlines (Yahoo Finance, 1h cache)
NeoGenomics (NEO) Stock Trades Up, Here Is Why
2026-07-09 22:15 · Yahoo
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
2026-07-09 11:05 · Yahoo
Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?
2026-07-08 14:32 · Yahoo
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
2026-07-07 11:05 · Yahoo
CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology
2026-07-02 22:41 · Yahoo
A Look Back at Testing & Diagnostics Services Stocks’ Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack
2026-06-26 11:52 · Yahoo
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
2026-06-25 11:05 · Yahoo
1 Unprofitable Stock for Long-Term Investors and 2 Facing Headwinds
2026-06-19 16:36 · Yahoo
NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?
2026-06-19 11:09 · Yahoo
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
2026-06-17 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.